Sugi Predict

Sugi Predict / Targets / CD2

CD2

T-cell surface antigen CD2 · P06729 · CD2 on Sugi Atlas →

69 patent compounds predicted against CD2, 60 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL31060461 SCHEMBL31060461 0.56 1/20
SCHEMBL19375812 SCHEMBL19375812 0.54 1/20
SCHEMBL10049951 SCHEMBL10049951 0.54 1/20
SCHEMBL19367902 SCHEMBL19367902 0.53 1/20
SCHEMBL22891909 SCHEMBL22891909 0.53 1/20
SCHEMBL23968131 SCHEMBL23968131 0.53 1/20
SCHEMBL21312758 SCHEMBL21312758 0.53 1/20
SCHEMBL22844368 SCHEMBL22844368 0.53 1/20
SCHEMBL15840391 SCHEMBL15840391 0.52 1/20
SCHEMBL15840412 SCHEMBL15840412 0.52 1/20
SCHEMBL31060963 SCHEMBL31060963 0.52 1/20
SCHEMBL19299795 SCHEMBL19299795 0.51 1/20
SCHEMBL21664077 SCHEMBL21664077 0.50 1/20
SCHEMBL19581485 SCHEMBL19581485 0.49 1/20
SCHEMBL31060302 SCHEMBL31060302 0.49 1/20
SCHEMBL19018674 SCHEMBL19018674 0.48 1/20
SCHEMBL7746029 SCHEMBL7746029 0.48 1/20
SCHEMBL15308347 SCHEMBL15308347 0.48 1/20
SCHEMBL19018807 SCHEMBL19018807 0.48 1/20
SCHEMBL22618578 SCHEMBL22618578 0.48 1/20

Clinical trials — most relevant to CD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma PHASE1/PHASE2UNKNOWN
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). PHASE1/PHASE2RECRUITING
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma PHASE1/PHASE2UNKNOWN
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies PHASE1/PHASE2RECRUITING
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1/PHASE2UNKNOWN
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies PHASE1/PHASE2UNKNOWN
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma PHASE1/PHASE2UNKNOWN
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies PHASE1/PHASE2UNKNOWN
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children PHASE2COMPLETED
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia PHASE2RECRUITING
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma PHASE1/PHASE2UNKNOWN
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL PHASE1/PHASE2UNKNOWN
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL PHASE2COMPLETED
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies PHASE1/PHASE2RECRUITING
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia PHASE1/PHASE2UNKNOWN
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma PHASE1/PHASE2UNKNOWN
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma PHASE2RECRUITING
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
A Phase I Dose Finding Study of MB-CART2219.1 PHASE1RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1UNKNOWN
To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors PHASE1RECRUITING
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. PHASE1UNKNOWN
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies PHASE1ACTIVE_NOT_RECRUITING
A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma PHASE1COMPLETED
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies PHASE1COMPLETED
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL EARLY_PHASE1UNKNOWN
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients EARLY_PHASE1ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD2 binder may also engage these)

ProteinNameSimilarity
Q6SZ61 — 1.000 Q6SZ61 →
P37998 — 1.000 P37998 →
P08920 — 1.000 P08920 →
P08921 — 0.994 P08921 →
B0CLX4 — 0.987 B0CLX4 →
Q9D9J7 — 0.987 Q9D9J7 →
Q9JLM2 — 0.985 Q9JLM2 →
Q9D7L8 — 0.985 Q9D7L8 →
Q86XK7 — 0.985 Q86XK7 →
Q80UL9 — 0.984 Q80UL9 →
Q95M19 — 0.984 Q95M19 →
P25446 — 0.984 P25446 →
P42071 — 0.984 P42071 →
Q9D2J4 — 0.984 Q9D2J4 →
P06332 — 0.983 P06332 →
P43432 — 0.983 P43432 →
Q29037 — 0.983 Q29037 →
Q95MD2 — 0.983 Q95MD2 →
C8AW47 — 0.982 C8AW47 →
P97710 — 0.982 P97710 →
Q4KLY3 — 0.982 Q4KLY3 →
Q90314 — 0.982 Q90314 →
P16872 — 0.982 P16872 →
Q3T113 — 0.982 Q3T113 →
Q8R4V1 — 0.982 Q8R4V1 →
Q924V5 — 0.982 Q924V5 →
Q9Z0K5 — 0.982 Q9Z0K5 →
A6QQC6 — 0.981 A6QQC6 →
Q96PD2 — 0.981 Q96PD2 →
P18181 — 0.981 P18181 →